TY - JOUR
T1 - An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
AU - Morandeau, Laurence
AU - Ioppolo, Joseph A.
AU - Alvarez de Eulate, Eva
AU - Mohamed, Shifaza
AU - Cullen, Danica
AU - Asad, Ali H.
AU - Francis, Roslyn J.
AU - Atkinson, Janette
N1 - Publisher Copyright:
© 2024 JoVE Journal of Visualized Experiments.
PY - 2024/5/24
Y1 - 2024/5/24
N2 - [68 Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP inhibitors (FAPIs) have demonstrated uptake in various types of cancers, including breast, lung, prostate, pancreatic and colorectal cancer. FAPI-PET also possesses a practical advantage over FDG-PET as fasting and resting are not required. [68 Ga]Ga-FAPI-46 exhibits enhanced pharmacokinetic properties, improved tumor retention, and higher contrast images than the earlier presented [68 Ga]Ga-FAPI-02 and [68 Ga]Ga-FAPI-04. Although a manual synthesis protocol for [68 Ga]Ga-FAPI-46 was initially described, in recent years, automated methods using different commercial synthesizers have been reported. In this work, we describe the development of the automated synthesis of [68 Ga]Ga-FAPI-46 using the iPHASE MultiSyn synthesizer for clinical applications. Initially, optimization of the reaction time and comparison of the performance of four different solid phase extraction (SPE) cartridges for final product purification were investigated. Then, the development and validation of the production of 0.6-1.7 GBq of [68 Ga]Ga-FAPI-46 were conducted using these optimized parameters. The product was synthesized in 89.8 ± 4.8% decay corrected yield (n = 6) over 25 min. The final product met all recommended quality control specifications and was stable up to 3 h post synthesis.
AB - [68 Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP inhibitors (FAPIs) have demonstrated uptake in various types of cancers, including breast, lung, prostate, pancreatic and colorectal cancer. FAPI-PET also possesses a practical advantage over FDG-PET as fasting and resting are not required. [68 Ga]Ga-FAPI-46 exhibits enhanced pharmacokinetic properties, improved tumor retention, and higher contrast images than the earlier presented [68 Ga]Ga-FAPI-02 and [68 Ga]Ga-FAPI-04. Although a manual synthesis protocol for [68 Ga]Ga-FAPI-46 was initially described, in recent years, automated methods using different commercial synthesizers have been reported. In this work, we describe the development of the automated synthesis of [68 Ga]Ga-FAPI-46 using the iPHASE MultiSyn synthesizer for clinical applications. Initially, optimization of the reaction time and comparison of the performance of four different solid phase extraction (SPE) cartridges for final product purification were investigated. Then, the development and validation of the production of 0.6-1.7 GBq of [68 Ga]Ga-FAPI-46 were conducted using these optimized parameters. The product was synthesized in 89.8 ± 4.8% decay corrected yield (n = 6) over 25 min. The final product met all recommended quality control specifications and was stable up to 3 h post synthesis.
UR - http://www.scopus.com/inward/record.url?scp=85195360931&partnerID=8YFLogxK
U2 - 10.3791/66708
DO - 10.3791/66708
M3 - Article
C2 - 38856210
AN - SCOPUS:85195360931
SN - 1940-087X
VL - 2024
JO - Journal of Visualized Experiments
JF - Journal of Visualized Experiments
IS - 207
M1 - e66708
ER -